24 December 2017

TIKOMED CEO WILL BE MODERATING THE ”EVOLVING BIOPHARMA BOARDS” AT THE EAST/WEST CEO MEETING PRECEEDING JPMORGAN HEALTH CONFERENCE

Adam Bruce, CEO of TikoMed will be moderating the ”Evolving Biopharma Boards” panel discussion at the East/West CEO meeting preceeding J.P. Morgan Healthcare Conference
Panelists will include the below seasoned Biopharma leaders:
Martin Babler, CEO, Principia Biopharma; William Heiden, President & CEO, AMAG Pharmaceuticals; Catherine Sohn, Chairman, BioEclipse Therapeutics
Moderator: Adam Bruce, CEO, TikoMed
Adam Bruce, says: I am deeply honored to lead the panel for such an important subject. In the pharma world it is of absolute essence to have an aligned chain of competence, starting with owners,followed by the board and finally management. Given the phases of pharma development, it is in my opinion essential,to balance an evolution with continuity. I am excited to hear the panelists thoughts and experiences on the subject.
East/West CEO is a networking forum for industry CEOs and decision makers in the life sciences. Attendees gain insights from presentations and discussion panels featuring CEOs from several of the world’s leading biopharmaceutical companies. Healthcare investors also attend.
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

4 March 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…
Read More
6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
SEE MORE